Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bristol-Myers Squibb (BMY – Research Report) and Envista ...

Indian generic drugmaker Dr Reddy's Laboratories reported a second-quarter profit that missed analysts' expectations on Tuesday, weighed down by pricing pressure in a competitive North American market ...

Reports of drug-related supply-chain issues were 40 percent less likely to result in drug shortages in Canada versus the United States, according to a new study.

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Alan Bash as the Company’s President of CARVYKTI ®. In this newly ...

Some people who took a new schizophrenia drug for a year improved with only a few side effects, but many dropped out of the research, the company announced Thursday.

Bristol Myers Squibb reported third-quarter earnings and revenue that blew past expectations on strong sales from its blood ...

2024 The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the first new type of antipsychotic medicine in decades. Bristol Myers ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

In this segment, Dr. Roxanna Mehran of the Mount Sinai Health System is talking about the Bristol-Myers Squibb-Janssen Librexia Clinical Trial Program. More information on the clinical trial and ...

Earlier in 2024, Bristol-Myers Squibb finalized a $14 billion deal to acquire Karuna Therapeutics and its promising psychosis drug, KarXT. However, the company’s stock declined after recording a ...

The Food and Drug Administration approved use of a naloxone nasal spray without a prescription last year, a move the agency said was designed to make the medication readily available in drugstores ...